Cipla inks partnership with China’s Qilu Pharma for cancer biosimilar
The partnership reflects Cipla’s confidence in the long-term potential of biosimilars and supports its strategy to build a strong oncology-focused portfolio.
· 9/4/2026, 9:41:06 AM· 2 min read
The partnership reflects Cipla’s confidence in the long-term potential of biosimilars and supports its strategy to build a strong oncology-focused portfolio.
Read original story →Related stories
business
Sensex rebounds 362 points, snaps 4-day losses on strong rally in metal, oil shares
business
Rupee rises 2 paise to close at 94.49 against U.S. dollar
business
Stock up on food to prepare for extreme weather, minister warns
business